Evidence map›Paper›PMID 25910598›Full record

ArticleTrends in cardiovascular medicine2015

Calm down when the heart is stressed: Inhibiting calmodulin-dependent protein kinase II for antiarrhythmias.

Dayue Darrel Duan

Open access · greenAbstract readEditorialComment
In one paragraph

Article in Trends in cardiovascular medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Synergistic antiarrhythmic mechanism of IJournal of translational medicine · 2025
    Article
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Dayue Darrel DuanThe Laboratory of Cardiovascular Phenomics, Center for Molecular Medicine, School of Medicine University of Nevada, Reno, NV; Department of Pharmacology, School of Medicine University of Nevada, Reno, NV. Electronic address: dduan@medicine.nevada.edu.
University of Nevada, Reno · US

Funding

The CLC-3 chloride channels in the heartR01HL113598 · NHLBI · UNIVERSITY OF NEVADA RENO · PI DUAN, DAYUE DARREL · 2013 to 2016
$1.4M
NHLBI NIH HHS HL113598NHLBI NIH HHS R01 HL113598
6 · The paper itself

Abstract

Ca(2+)/calmodulin-dependent protein kinase II (CaMKII) plays a pivotal role in many regulatory processes of cellular functions ranging from membrane potentials and electric-contraction (E-C) coupling to mitochondrial integrity and survival of cardiomyocytes. The review article by Hund and Mohler in this issue of Trends in Cardiovascular Medicine highlights the importance of the elevated CaMKII signaling pathways under stressed conditions such as myocardial hypertrophy and ischemia in the detrimental remodeling of ion channels and in the genesis of cardiac arrhythmias. Down-regulation of the elevated CaMKII is now emerging as a powerful therapeutic strategy for the treatment of cardiac arrhythmias and other forms of heart disease such as hypertrophic and ischemic heart failure. The development of new specific and effective CaMKII inhibitors as therapeutic agents for cardiac arrhythmias is challenged by the tremendous complexity of CaMKII expression and distribution of multi isoforms, as well as the multitude of downstream targets in the CaMKII signaling pathways and regulatory processes. A systematic understanding of the structure and regulation of the CaMKII signaling and functional network under the scope of genome and phenome may improve and extend our knowledge about the role of CaMKII in cardiac health and disease and accelerate the discovery of new CaMKII inhibitors that target not only the ATP-binding site but also the regulation sites in the CaMKII signaling and functional network.

Indexed as

Arrhythmias, CardiacCalcium-Calmodulin-Dependent Protein Kinase Type 2HumansCalcium-Calmodulin-Dependent Protein Kinase Type 2

Identifiers

PMID25910598
PMCPMC4699401
OpenAlexW2035807998

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.